Synthesis and SAR studies of dual AKT/NF-κB inhibitors against melanoma

Area of Science:

• Oncology
• Molecular Biology
• Medicinal Chemistry

Background:

• The AKT and NF-κB signaling pathways are crucial in cancer development and progression.
• These pathways are frequently upregulated in various cancers, including melanoma.
• Compound 1 (BI-69A11) was previously identified as an inhibitor of both AKT and NF-κB pathways.

Purpose of the Study:

• To conduct Structure-Activity Relationship (SAR) studies to discover novel AKT and NF-κB pathway inhibitors.
• To develop fluorinated derivatives with enhanced cellular potency and efficacy against cancer cell lines.
• To evaluate the in vivo efficacy of a representative derivative in a melanoma xenograft model.

Main Methods:

• Structure-Activity Relationship (SAR) analysis of novel fluorinated compounds.
• Assessment of cellular potency through inhibition assays for AKT and IKKs.
• In vitro cytotoxicity testing against melanoma, breast, and prostate cancer cell lines.
• In vivo efficacy evaluation in a melanoma xenograft mouse model.

Main Results:

• Novel fluorinated derivatives of Compound 1 were synthesized, exhibiting increased cellular potency.
• These derivatives effectively inhibited the AKT and IKKs (key components of the NF-κB pathway).
• Selected compounds showed significant toxicity against melanoma, breast, and prostate cancer cell lines.
• A representative fluorinated derivative demonstrated promising anti-tumor efficacy in an in vivo melanoma xenograft model.

Conclusions:

• The SAR studies successfully identified novel fluorinated AKT and NF-κB pathway inhibitors with enhanced potency.
• These compounds exhibit broad anti-cancer activity in vitro and promising in vivo efficacy.
• The developed compounds represent potential therapeutic agents for treating cancers driven by AKT and NF-κB signaling.